BioRestorative Therapies, Inc. (BRTX) is a Biotechnology company in the Healthcare sector, currently trading at $0.25. It has a SharesGrow Score of 53/100, indicating a mixed investment profile with 2 out of 7 criteria passed.
Valuation: BRTX trades at a trailing Price-to-Earnings (P/E) of -0.2 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 0.01.
Financials: revenue is $359,700, +62.1%/yr average growth. Net income is $14M (loss), growing at -0.9%/yr. Net profit margin is -3959.4% (negative). Gross margin is 93.4% (+227.7 pp trend).
Balance sheet: total debt is $0 against $356,744 equity (Debt-to-Equity (D/E) ratio 0, conservative). Current ratio is 0.84 (tight liquidity). Debt-to-assets is 0%. Total assets: $4M.
Analyst outlook: 3 / 3 analysts rate BRTX as buy (100%) — strong consensus.
SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 58/100 (Partial), Past 0/100 (Fail), Health 50/100 (Partial), Moat 50/100 (Partial), Future 100/100 (Pass), Income 10/100 (Fail).
